Contributing Member of the Healthcare Councils

Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.

GLG News by this Author

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

Succesful new treatment for Lupus

November 10, 2009

Analysis of:GSK & HSG say belimumab met primary endpoints in BLISS-76 phase-3 trials | www.pharmabiz.com

Human Genome Sciences has a potential new and successful therapy for Lupus.

Update on tocilizumab treatment for RA

October 22, 2009

Analysis of:Data from LITHE study shows RA particularly affects the small joints of the hands and feet | www.pharmabiz.com

Impressive results for tocilizumab treatment of RA.

denosumab approval delayed

October 21, 2009

Analysis of:denosumab approval delayed | www.pharmatimes.com

Amgen's osteoporosis drug denosumab is delayed fda approval.

Pfizer fine for inappropriate bextra marketing

October 19, 2009

Analysis of:Pfizer Subsidiary Hit With Record Fine For Misbranding Bextra | online.wsj.com

Fines for inappropriate marketing are part of the cost of doing business for Big Pharma. However they seem to be changing their marketing to physicians due to government scrutiny.

Newer info on Enbrel, not really that surprising.

October 18, 2009

Analysis of:New data from PRESTA trial demonstrate the benefit of Enbrel in patients with psoriasis & psoriatic arthritis | www.pharmabiz.com

More good results for enbrel in psoriasis and psoriatic arthritis.

Another tnf blocking agent?

October 18, 2009

Analysis of:Cimzia®, the only PEGylated anti-TNF, approved in Europe and available in a syringe designed in partnership with OXO Good Grips® | www.pipelinereview.com

Cimzia is another tnf blocking med, approved for RA and Chron's.

NICE guidelines for usage of biologics and possible implications in the US

September 22, 2009

Analysis of:New NICE Guidelines To Help Thousands Of People With Rheumatoid Arthritis | www.medicalnewstoday.com

The NICE guidelines from the UK for biologic usage in treatment of RA are thorough and interesting. They include sensible recommendations for early referral for evaluation of RA, and also treatment recommendations for biologic usage that if applied in the US market could affect various drug makers substantially.

Mastinib for treatment of Rheumatoid arthritis

September 22, 2009

Analysis of:Arthritis Drug Shows Promise In Clinical Trial | www.medicalnewstoday.com

Mastinib is a novel new drug, and may have a future role in treatment of rheumatoid arthritis based on recent evidence.

Small molecule inhibitors in RA.

September 22, 2009

Analysis of:Galapagos clinical trial for GLPG0259 | tu.glgroup.com

Kinase inhibitors and other small molecule therapeutics in treatment of RA, huge potential market.

Is a new delivery system for a old drug such a big deal?

September 22, 2009

Analysis of:Wyeth Launches New Innovative Delivery System For Enbrel(R) (etanercept) | www.medicalnewstoday.com

The new delivery system that Wyeth is presenting for Enbrel might make a difference in acquiring new patients.

Dissapointing results

May 14, 2008

Analysis of:Genentech and Biogen Idec Announce Top-Line Results From Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus | www.pipelinereview.com

Rituxan is no better than placebo in SLE in this study. Another med bites the dust when tested for SLE. Further details of this study need to be reviewed.

Page : 11 to 11 of 11

Subscribe to Updates

By RSS